Splice Bio, a gene therapy company based on technology developed in the Muir Lab at Princeton University, announced today that it has appointed JeanPhilippe Combal as Chairman of its Board of Director...
Read more
SparingVision (“the Company”), a genomic medicine company focused on ocular diseases, today announces a €44.5 million financing round. The round was led by 4BIO Capital (“4BIO”) and UPMC Ent...
Read more
Sperogenix Therapeutics, a platform company dedicated to developing and commercializing rare disease therapeutics in China, and Minoryx Therapeutics, a company that specializes in the development of i...
Read more
LAVA Therapeutics, a biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer therapies, today announced the closing of an oversubscribed $83 millio...
Read more
The oversubscribed round was co-led by Ysios Capital and INKEF Capital; Lundbeckfonden Ventures and LSP joined the syndicate. Founding investor, BioGeneration Ventures (BGV) and the regional economic ...
Read more
El “Estudio de inversión en el sector de las ciencias de la vida y la salud en Cataluña 2020” revela la buena salud del ecosistema, que casi ha igualado durante el primer semestre de 2020 el cap...
Read more
Raising private funding is essential for an innovation project to progress and reach market. ITEMAS 2nd webinar of the series about Investment in Covid-19 times tackled the key steps for entrepreneurs...
Read more
Ona Therapeutics, which is focused on the discovery and development of therapeutic biologics to treat metastatic cancer, announces today the closing of a €30 million Series A financing, with partici...
Read more
Ysios Capital, a leading biotechnology venture capital firm in Spain, today announced its third fund, Ysios BioFund III, with a committed amount of € 155M and a final target size of € 200M.
Read more
AM-Pharma B.V. (‘AM-Pharma, the Company’), a clinical stage biopharmaceutical company, leading in the development of a treatment for acute kidney injury (AKI) with its innovative recombinant human...
Read more
Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that it closed a $40 million Series D financing. New investor Medicxi led the round, with
Read more
Pfizer and Vivet to collaborate on development of potential breakthrough therapy for Wilson disease
Read more
A new technique allows the design of solid materia...
El estudio realizado sobre una muestra significati...
Dámaso Molero: “There are great opportunities in Latin America for ...
Inbiomotion SL has announced that Alta Life Sciences has led its si...
